Introduction
Isoxsuprine, as other beta-adrenergic drugs, is a potent clinically used tocolytic agent [4, 13] , increasingly used in the treatment of premature labor [8] . In the past, the major limiting factors in the use of isoxsuprine were its tendencies to produce tachycardia and hypotension. Glucocorticoids are commonly used as an adjunct to beta-adrenergic drugs in the management of premature labor to accelerate fetal lung maturity [18] . Few reports in the American literature [10, 15, 16, 26] , detail adverse maternal cardiovascular effects of beta-adrenergic drugs, especially when they are used in combination with glucocorticoids. The European literature reports several cases of cardiorespiratory complications related to the combined usage of betamimetic drugs and glucocorticoids [9, 12, 24, 27] . We have recently seen a potentially serious complication in a mother treated antenatally with isoxsuprine and dexamethasone. This was our first case of pulmonary edema seen during a period of five years usage of isoxsuprine.
Case report
A 28 year old woman, gravida 2, para 1, was admitted to the maternity ward with painful contractions in the 32nd week of her second pregnancy. In her first pregnancy, she delivered prematurely in the 32nd week, a girl of 2300 g. The patient had no history of cardiac or pulmonary disease. Physical examination disclosed a thin woman. 48kg B. W. with no signs of cardiopulmonary disease. The uterine fundus measured was compatible with gestational age. Therapy with intravenous isoxsuprine was begun with initial rate of 0.04 mg/min and increment of 0.04 mg/min every 15-30 min up to 0.32 mg/min (a total dose of 560 mg/48 hr). She was given two doses of intramuscular dexamethasone 12 mg every 24 hours. Forty-eight hours later, the patient experienced shortness of breath and chest pain. Examination disclosed wet rales over both lung fields; pulse rate was 120 beats/min, blood pressure 130/80 mmHg, respiration 34 breaths/min, temperature 37 °C. AnECG showed sinus.tachycardia. The hematocrit was 26 % and electrolytes were normal except J. Perinat. Med. 1 1 (1983) the serum potassium which was 3 mEq/liter. Arterial blood gases on 0.5 FiU2 ^a ce mask disclosed: Ρθ2 80 torr PCO2 28 torr and P H 7-43-There was a positive fluid balance of 1.7 liters in the first 24 hours and 5.2 liters in the next 24 hours. Treatment with iv 40 mg furosemide, oxygen mask and 25 mg meperidine was begun after discontinuation of isoxsuprine. She was placed in an erect position. Over the next four hours the clinical state improved greatly, the respiration declined to 20 breaths per minute, pulse'rate to 90/min and urine output was three liters in 24/h. However, examination of lung disclosed wet rales over the base of lung field and arterial blood gases on room air were Ρθ2 60 torr, PCO2 32 torr. Eight hours from the start of dyspneic attack, the lung fields were clear and blood gases returned to the normal values. One day later, oral isoxsuprine 5 mg every three hours were started. The patient tolerated therapy well, the uterine contractions were abolished and she was discharged on a regimen of oral isoxsuprine 80 mg a day at the 34 weeks' gestation. She returned at the 38 weeks' gestation two days after stopping medication and delivered a 2860 g infant with APGAR scores of 9 and 10 at 1 and 5 minutes, respectively. The infant did well in the nursery. The patient has been followed up to six weeks. There was no clinical evidence of cardiovascular disease or renal impairment. The chest x-ray film and ECG were both normal.
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Discussion
Preterm delivery affects approximately 6-10% of all births and is a leading cause of perinatal mortality [22] . The treatment of preterm labor with tocolytic agents has become widespread practice of obstetrics. However, maternal treatment with tocolytic agent is not necessarily harmless. Mild to severe side effects and complications have been sporadically reported with the use of tocolytic agents [9, 12, 14, 17, 21, 23, 26, 27, 34] . Their implications in pulmonary edema are summarized in Table I . Isoxsuprine, although demonstrated to be of significant value in a randomized controlled study [8] , has major limiting factors -a tendency to produce tachycardia and hypotension. However, these problems can be minimized if bolus administration is avoided [19] . In a retrospective study of 343 women [24] treated with isoxsuprine or terbutaline, the incidence of severe cardiovascular complications such as pulmonary edema and myocardial ischemia was higher among women treated with terbutaline than among those treated with isoxsuprine. During the last five years, we have gained experience with the use of isoxsuprine in women for preterm labor. Our protocol today for the management of preterm labor, includes an initial intravenous administration of isoxsuprine and a following oral therapy 12-36 hours later. The initial intravenous rate is 0.04 mg/min with an increment of 0.04 mg/min every 15-30 min up to 0.32 mg/min or a total dose of 280mg/24h followed by oral administration of 10mg every 1-3 hours. These doses are much smaller than those reported previously [24] though potent enough for abolishing uterine contractions. Pulse rate is kept below 120 beats/min. Serum potassium is kept between 3.5-4 mEq/L and fluid intake is limited to 2-3 Liters/24 hours. Dexamethasone is administered when gestational weeks are 27-33 in two divided doses of 12 mg every 24 hours. With such treatment regimen over a period of five years, only one out of 150 of our patients developed severe cardiovascular complications, i. e. pulmonary edema. The patient described here was young, with no prior cardiovascular disease. It seems that the generous fluid intake during the period of isoxsuprine and dexamethasone therapy contributed to the sudden episode of pulmonary edema. The vulnerability of the pregnant patient treated with beta-adrenergic agents and gjucocorticoid drugs to the sudden onset of cardiac embarrassment and pulmonary edema depends on the development of a compensated high cardiac output state during gestation. Isoxsuprine, as well as other beta-adrenergic agents increases the maternal pulse rate, causes peripheral vasodilatations and redistribution of the blood flow to several organs and increases the cardiac output [6, 7] . Betaadrenergic agents may also have direct cardiotoxic effect [29] or may produce post capillary pulmonary venoconstriction. Each of these effects can contribute to maternal heart failure. Corticoids with its mineralocorticoid activity of sodium and water retention, may bring about heart failure and pulmonary edema. Another factor that may place the pregnant patient at risk for cardiac failure with beta-adrenergic therapy, include anemia [20, 25] , pre-existing cardiac disease, hypokalemic and liberal use of crystalloid solutions [2, 16] . Anemia may lower peripheral vascular resistance by reducing blood viscosity, thus increasing cardiac output [20] . Hypokalemia may cause conduction and rhythm disturbances. In addition to the maternal problems, several neonatal complications have been reported after maternal treatment with beta-adrenergic agents. Most commonly recognized are hypoglycemia, hypotension, hypocalcemia and death [1, 5, 11, 28] .
In the study of BENEDETTI [3] of two women with pulmonary edema using SWAN GANZ catheter, it was shown that except for high cardiac output, other cardiac indices such as mean arterial pressure, pulmonary artery pressure, pulmonary artery wedge pressures, colloid osmotic pressure and ejection fraction, were within the normal limits. It was suggested that a transient increase in pulmonary capillary permeability was the most likely etiology of pulmonary edema. However, the protein content in the edema fluid and the blood was not detected in that study. Despite the fact that pulmonary edema seen in the present and other reports [9, 10, 15, 16, 24, 26, 27] was easily and quickly controlled, it is potentially dangerous. Therefore, further studies are necessary to elucidate the mechanism of pulmonary edema during the treatment with beta-adrenergic drugs. At the present time, it would seem prudent to include the following measure in the clinical management of patients receiving beta-adrenergic tocolytic therapy. Cardiovascular signs and symptoms should be monitored frequently, fluid balance and even fluid restriction should be accurately recorded and tachycardia greater than 120bpm for prolonged periods should be avoided. Baseline blood samples for determination of hemoglobin, hematocrit and electrolytes are indicated especially in those patients having prolonged intravenous beta-adrenergic treatment. As soon as normal signs and symptoms are detected further studies should be carried out, including electrocardiography, arterial blood gases, and echocardiography.
Summary
A case of maternal pulmonary edema occurring in a patient in the 32nd week of gestation is presented. This was our first case of pulmonary edema seen during a period of five years' usage of isoxsuprine in the treatment of premature labor. The patient presented was 28 years old, gravida 2, para 1, admitted to the maternity ward with premature uterine contractions. Her past history eliminate cardiac or pulmonary disease. Isoxsuprine therapy was begun with initial dose of 0.04 mg/min. and increased to 0.32 mg/min., the total dose administered was 560 mg during 48 hours. During this period she was given in dexamethasone 24 mg. Fluid balance on the first day of the treatment was + 1.7 liters and on the second day +5.2 liters. Forty-eight hours from the commencement of the treatment, the patient experienced shortness of breath and chest pain. Physical examination disclosed wet rales over both lungs, sinus tachycardia and tachypnea. Laboratory examination disclosed hypopotassemia of 3 mEq/liter, hypoxemia ( 2 °f 80 torr on 0.5 FiU2 face mask) with mild hyperventilation 28 torr ?CO2 with normal ph 7.43.
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Recognition of the early signs of pulmonary edema enable swift clinical diagnosis and steps to be taken to prevent disasterous condition due to progressive hypoxemia. The prompt treatment in this complication includes discontinuation of isoxsuprine and fluid administration, placement of the patient in an erect position, intravenous furosemid 40 mg, oxygen supplement by face mask and 25 mg of meperidine. The patient's condition dramatically improved though the lung fields became completely clear from wet rales only eight hours from the start of dyspneic attack. A day later oral isoxsuprine was commenced in a dose of 5 mg every three hours. This treatment was continued up to the 38th week of gestation when she delivered normally two days after discontinuation of the treatment. It is suggested that fluid overload was the event that triggered this complication, besides, it seems that our protocol for the treatment of premature labor seems safe. The ethiology of pulmonary edema in this case was discussed. Ce traitement a ete poursuivi jusqu'ä la 38eme semaine de gestation, date ä laquelle °la patiente accoucha normalement 2jours apres l'arret du traitement. Les auteurs suggerent que la surcharge liquidienne a ete l'element declencheur de cette complication; bien plus, ils estiment que leur protocole de traitement de l'accouchement premature n'est pas risque. L'etiologie de l'oedeme pulmonaire est discutee dans cette observation.
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